Adenoviral vectors are widely used in cancer gene therapy. After systemic administration however, the majority of the virus homes to the liver and the expressed transgene may cause hepatotoxicity. To restrict transgene expression to tumor cells, tumor-or tissuespecific promoters are utilized. The tumor antigen epithelial glycoprotein-2 (EGP-2), also known as Ep-CAM, is expressed in many cancers from different epithelial origins. In this study, the EGP-2 promoter was shown to restrict the expression of luciferase and thymidine kinase in an adenoviral context in different cell lines. In vivo, the EGP-2 promoter mediated efficient expression of luciferase in tumors but showed a 3-log lower activity in liver tissue when compared with the cytomegalovirus (CMV) promoter. Similarly, the EGP-2 promoter mediated specific cell killing after ganciclovir treatment in EGP-2-positive cells. Moreover, in vivo, this treatment regiment did not cause any rise in the liver enzymes aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT), demonstrating absence of liver toxicity. In contrast, CMV-mediated expression of thymidine kinase in combination with ganciclovir treatment resulted in high ASAT and ALAT values. This study demonstrates the value of the EGP-2 promoter to restrict transgene expression to a broad range of tumor types, thereby preventing liver toxicity.
Introduction
Cancer is a major cause of death, indicating that new treatment methods need to be developed. In this regard, cancer gene therapy has shown encouraging results in a clinical setting. 1, 2 One gene therapeutic approach is to introduce so-called suicide genes into tumor cells. Expression of suicide genes will result in enzymes that can convert nontoxic prodrugs into toxic metabolites. The potency of this approach has recently been demonstrated in a clinical trial for human malignant glioma where the median survival time increased from 37.7 to 62.4 weeks. 2 To achieve efficient transfer of these suicide genes, vectors are utilized for the delivery to the malignant tissue. One of the most efficient vectors used is the adenovirus. A major problem of adenoviruses however is their lack of tumor specificity. When adenoviruses are administrated systemically, most of the virus homes to the liver, 3 where the expressed suicide gene can cause severe liver toxicity. 4, 5 To increase the specificity of the adenovirus, several solutions have been put forward.
One approach is to modify the tropism of the adenovirus to readdress the virus to the tumor tissue, as has been reviewed previously. 6 Another solution is to restrict the expression of suicide genes to tumor cells utilizing tumor-or tissue-specific promoters (tsp), as has been reviewed by Nettelbeck et al. 7 However, most tsp are only applicable for a certain type of cancer. For example, the tsp human alpha-lactalbumin (hALA) and ovine betalactoglobulin (oBLG) have been utilized for selective gene expression in breast tissue, 8 the prostate-specific enhancing sequence (PSES) promoter for the selective expression in prostate cancer 9, 10 and the tyrosinase promoter for the selective expression in melanoma. 11 We report here the suitability of the epithelial glycoprotein-2 (EGP-2) promoter for suicide gene therapy. EGP-2, also referred to as Ep-CAM or 17-1A, is an antigen overexpressed in the majority of epithelial derived cancers, such as breast, pancreas, gastrointestinal, respiratory and urinary tract tumors [12] [13] [14] and is exploited for immunotherapy. 15 Most importantly for retargeting purposes, the expression of EGP-2 is absent in mature hepatocytes. 16 We therefore hypothesized that the EGP-2 promoter is a good candidate to restrict the expression of suicide genes to a broad range of tumor cells, thereby untargeting the liver.
In the current study, we demonstrate the potential of a 3.4 kb EGP-2 promoter fragment to restrict transgene expression to tumor cells both in vitro and in vivo in an adenoviral context. However, due to limited space in the adenoviral genome for the introduction of spacious expression cassettes, 17 this promoter fragment may be of limited use for further applications. Therefore, we truncated the 3.4 kb EGP-2 promoter fragment to 1.2 kb to increase the potential applications of this promoter. We and others previously demonstrated that a truncated fragment of 1.1 kb remained active and specific. 12, 18 However, these studies were not performed in an adenoviral context where upstream adenoviral sequences might override the tumor selectivity of a promoter. 19 A truncated 1.2 kb EGP-2 promoter fragment was utilized in this study to control the expression of the reporter gene luciferase or the suicide gene SR39 thymidine kinase (SR39TK) in an adenoviral context. Thymidine kinase (TK) can phosphorylate the prodrug ganciclovir (GCV) eventually resulting in toxic metabolites, causing termination of DNA replication after which cell death occurs. SR39TK is a mutant TK displaying superior sensitivity to GCV compared to wild-type TK. 20, 21 In this study, we demonstrate that the EGP-2 promoter mediates efficient and selective killing of tumor cells in vitro and maintains activity and selectivity in vivo in an adenoviral context. We show that the EGP-2 promoter is a promising tool in cancer gene therapy to tackle a broad range of tumor types.
Materials and methods

Cell culture
The human colon carcinoma cell lines WiDr and LS174T, the ovarian cancer cell line Ovcar-3, the human colorectal adenocarcinoma cell line SW948, the astrocytoma cell line U373 and the transformed human embryonic kidney cell line (HEK293) were all purchased from the American Type Culture Collection (ATCC, Manassas, VA). The human small cell lung carcinoma (SCLC)-derived cell line GLC-1 was kindly provided by Dr LFMH de Leij (University Hospital Groningen, Groningen, The Netherlands). 22 WiDr, LS174T, GLC-1, Ovcar-3 and SW948 were all cultured in Dulbecco's modified Eagle's medium (DMEM) containing glutamine (Gibco Invitrogen Corporation, Breda, The Netherlands), supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Bio Whittaker Europe, Verviers, Belgium), penicillin (100 IU/ml) and streptomycin (100 IU/ml) (Gibco). U373 and HEK293 were cultured in DMEM/nut mix-F12 (Gibco) supplemented with 10% FBS, 2 mM glutamine (Gibco), penicillin (100 IU/ml) and streptomycin (100 IU/ ml) (Gibco). All cells were grown at 371C in a humidified 5% CO 2 atmosphere.
Reverse transcription-polymerase chain reaction To determine endogenous EGP-2 promoter activity, the EGP-2 RNA levels of the cancer cell lines were analyzed by reverse transcription-polymerase chain reaction (RT-PCR). RNA extraction was performed from frozen pellets, containing at least 5 Â 10 6 cells, using TRIzol Reagent (Gibco), according to the manufacturer's protocol. The total RNA was used as a template to produce cDNA using the Reverse Transcription System (Promega, Madison, WI). The antisense primer specific for EGP-2 (RPepcam 23 ) and the antisense primer specific for the housekeeping gene small nuclear ribonucleoprotein specific A protein U1A (snRNP U1A) (primerU1A2 24 ) were used in a single reaction. One-sixteenth of the resulting cDNA was used as a template for subsequent PCR for EGP-2 or snRNP U1A in separate reactions using the antisense primers combined with the sense primers for EGP-2 (FPepcam 23 ) or snRNP (snRNP U1A1 24 ). SnRNP U1A analysis served as a control for RNA quality. Cycle conditions were as described. 23 For both snRNP U1A and EGP-2 PCR assays, 40 cycles were run on an Eppendorf Mastercycler Gradient (Eppendorf, Hamburg, Germany).
Construction of the adenoviral vectors
All recombinant vectors were constructed through homologous recombination in Escherichia coli using the AdEasy system. 25 The transgene cassettes were cloned in the E1 region of the E1-and E3-deleted adenoviral backbone. Figure 1 gives an overview of the constructed adenoviral vectors.
The BglII-SacII fragment of the EGP-2 promoter, 3432 bp (À3340 to þ 91, containing the transcription start site), 26 was subcloned in pBluescript and subsequently cloned into the KpnI-XhoI sites of pShuttleGL3B. pShuttleGL3B is the pShuttle vector 25 in which the multiple cloning site is replaced with a fragment containing the multiple cloning site, the luciferase gene and the simian virus 40 polyadenylation signal from pGL3Basic (Promega). 19 The resulting vector was named pShGL3BEGP-2 3.4 kb.
Restriction of the 3.4 kb EGP-2 promoter fragment with EcoRI resulted in truncation of the EGP-2 promoter to 1162 bp (À1071 to þ 91, containing the transcription start site). The plasmid containing the truncated EGP-2 promoter fragment driving the expression of luciferase in the sense orientation (pShuttleGL3BEGP-2 1.2 kb) was obtained by EcoRI-EcoRI restriction of the 3.4 kb EGP-2 promoter, subloned in pGL3Basic (Promega) and subsequently cloned into the KpnI-BstBI sites in pShuttle-GL3BEGP-2 3.4 kb, thereby replacing the 3.4 kb EGP-2 promoter fragment for the 1.2 kb EGP-2 promoter fragment. The plasmid containing the truncated 1.2 kb EGP-2 promoter fragment controlling the expression of luciferase in the antisense orientation (pShuttleEGP-2 1.2 kb reverse) was constructed by NheI-SalI restriction of pShuttleGL3BEGP-2 1.2 kb and cloned into the pShuttle vector. 25 As a control, AdGL3BCMV 19 was used, containing the cytomegalovirus (CMV) promoter and the luciferase gene and simian virus 40 polyadenylation signal from pGL3Basic (Promega).
The vectors generated to drive the expression of SR39TK were termed pShEGP-2 SR39TK and pShCMV SR39TK. The SR39TK gene was a kind gift from Dr ME Black (Washington State University, Washington, USA). SR39TK was obtained from the plasmid pET23d:SR39 20 by PCR amplification using the primers 5 0 -ATGGATC CACCATGGCTTCGTACCCCTGCCA-3 0 and 5 0 -AT GCGGCCGCGTTAGCCTCCCCCATCTCCC-3 0 . The PCR-amplified fragment was subcloned in pcDNA3.1 and subsequently cloned into the HindIII-EcoRV sites of pShuttleCMV, 25 generating pShCMV SR39TK. pShEGP-2 SR39TK was obtained by cloning the EGP-2 1.2 kb fragment from pShGL3BEGP-2 1.2 kb into pShuttle 25 by restriction with KpnI-XhoI and insertion of SR39TK from pShCMV SR39TK by means of BglII-PmeI restriction.
The resulting viruses were named as described in Figure 1 . All viruses were purified by double density gradient centrifugation, followed by dialysis against 5% sucrose in 10 mM Tris pH 8.0 and 2 mM MgCl 2 . The viruses were aliquoted and stored at À801C until usage. The virus titer was determined by conventional limiting dilution on 293 cells.
Luciferase experiments
The activity of the EGP-2 promoter in an adenoviral context was analyzed by infection of cells with luciferaseencoding viruses. Cells were plated at 50 000 cells/well in a 24-well plate (Gibco BRL). The following day, the cells were infected at an m.o.i. of 10 or 100 PFU per cell with the indicated viruses, in medium containing 2% FBS (infection medium). After 1 h, medium containing 10% FBS was added. At 48 h after infection, the cells were lysed with Cell Culture Lysis Buffer (Promega) and the resultant lysates were analyzed with the Luciferase Assay System (Promega) on a Lumicount luminometer (Packard, Groningen, The Netherlands). Data are expressed as relative light units (RLU).
Cell viability assay
The activity and specificity of cell killing due to the expression of TK followed by GCV treatment was measured utilizing a CellTiter 96
s Aqueous Non-Radioactive Cell Proliferation Assay (MTS assay) (Promega). Cells were plated at 10 000-50 000 cells/well in a 96-well plate. The following day, the cells were infected with an m.o.i. of 10 or 100 PFU per cell AdCMV SR39TK or AdEGP-2 SR39TK. After 24 h, GCV was added and cell viability was measured after 48 h according to the manufacturer's protocol. The remaining cells were fixated with formalin solution (Sigma, Zwijndrecht, The Netherlands) and stained with gentian violet (Sigma) (1% in 70% EtOH).
Animal experiments
For in vivo experiments, female C57BL/6 mice (Harlan, Leiden, The Netherlands) and female BALB/c nu/nu mice of 6-8 weeks were used. All in vivo experiments were reviewed and approved by the Animal Experiments Committee (DEC) of the University Groningen, The Netherlands. 
Expression profile (luciferase).
To analyze the luciferase expression under control of the 3.4 kb EGP-2 promoter fragment in nontarget mice organs, C57BL/6 mice received 10 9 PFU of AdGL3BEGP-2 3.4 kb (n ¼ 3) or AdGL3 BCMV (n ¼ 3) intravenously via the orbital plexus. After 2 days, the livers, lungs, kidneys, spleens, intestines, stomachs and hearts were removed to measure luciferase expression. For analysis of the activity of the 3.4 kb EGP-2 promoter fragment in target tumor tissue, 2 Â 10 7 cultured LS174T cells were inoculated subcutaneously into both flanks of BALB/c nu/nu mice. When the tumors reached a diameter of 6-8 mm, the tumors were injected with 5 Â 10 8 PFU of either AdGL3BEGP-2 3.4 kb (n ¼ 2) or AdGL3BCMV (n ¼ 2). After 2 days, the animals were killed and tumors were resected for luciferase activity.
All the organs and tumors were rapidly frozen on dry ice-ethanol and stored at À801C until assayed. On the day of analysis, the organs and tumors were ground into fine powder with a pestle and mortar in an ethanol/dry ice bath. The tissue powders were lysed with Cell Culture Lysis Buffer (Promega) and, after three cycles of freezethawing, centrifuged and the recovered supernatants were analyzed with the Luciferase Assay System (Promega) on the Luminocount (Packerd). Protein concentration was based on the assumption that one-third of the total tissue wet weight is protein to normalize the RLU values.
Toxicity profile (SR39TK). For determination of the toxicity caused by TK expression and GCV treatment, 5 Â 10 8 PFU of AdEGP-2 SR39TK (n ¼ 4) or AdCMV SR39TK (n ¼ 4) was injected intravenously. After 24 h, GCV (75 mg/kg body weight) was intraperitoneally administrated once a day for 3 consecutive days. Following GCV treatment, the mice were killed, the livers were photographed and aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) blood values were determined at the Laboratory Center University Hospital Groningen.
Results
Analysis of endogenous EGP-2 promoter activity
To determine the activity of the endogenous EGP-2 promoter, human cell lines were analyzed by RT-PCR for EGP-2 transcripts (Figure 2 ). Because the primers were designed to flank splice junctions, discrimination was possible between amplification of spliced cDNA and coamplification of contaminating genomic DNA. 24, 23 The colon carcinoma cell lines WiDr and LS174T, the colorectal adenocarcinoma cell line SW948 as well as the ovarian cancer cell line Ovcar-3 showed a clear band around 200 bp, which represented EGP-2 cDNA. In contrast, there was no EGP-2 expression in the SCLCderived cell line GLC-1.
The 3.4 kb EGP-2 promoter fragment remains specific and active in an adenoviral context in vitro The 3.4 kb EGP-2 promoter was utilized to regulate the expression of the reporter gene luciferase to determine the activity and specificity of this promoter in an adenoviral context. In EGP-2-positive cell lines, the EGP-2 promoter efficiently controlled the expression of luciferase with levels up to nearly 30% when compared with the strong constitutively active CMV promoter (Figure 3a and b) .
On the other hand, in EGP-2-negative cell lines, the EGP-2 promoter activity was less than 0.2% of the CMV activity in both cell lines. The EGP-2-positive cell line Ovcar-3 and the negative cell line U373 showed comparable CMV-controlled luciferase activity (Figure 3a) . However, the EGP-2 promoter activity in the negative cell line U373 was almost 2-log less compared to the positive cell line Ovcar-3, indicating the outstanding specificity of the 3.4 kb EGP-2 promoter.
The 3.4 kb EGP-2 promoter fragment controls specific and efficient expression in an adenoviral context in vivo The 3.4 kb EGP-2 promoter fragment was analyzed in an adenoviral context for its potential to control selective transgene expression in vivo. Mice were injected intravenously with AdGL3BEGP-2 3.4 kb or AdGL3BCMV, and seven major organs were examined for luciferase activity. In the kidney, lung, intestine, heart and stomach, the CMV-controlled luciferase expression was at least 2-log lower compared to the luciferase expression in the liver (Figure 3c ). The biodistribution of both viruses was similar, as shown by the intestine samples in which luciferase expression driven by the 3.4 kb EGP-2 promoter fragment was comparable with CMV promoter-driven expression. Importantly, luciferase expression in the liver
EGP-2 Figure 2 Analysis of endogenous EGP-2 promoter activity. The RNA levels of different cell lines were analyzed by reverse transcription followed by PCR. The housekeeping gene snRNP U1A was used as control. SnRNP U1A RNA was detected at the position of 215 bp. EGP-2 RNA was detected at 220 bp in EGP-2-positive cell lines.
was over 3-log less for animals treated with Ad-GL3BEGP-2 3.4 kb, compared with liver tissue of animals treated with AdGL3BCMV ( Figure 3c ). In another tissue easily infected by adenoviruses, the spleen, the EGP-2-controlled luciferase expression was less than 0.1% of that of the CMV promoter.
To examine whether the 3.4 kb EGP-2 promoter controlled efficient expression in tumor tissue in vivo, AdGL3BEGP-2 3.4 kb or AdGL3BCMV was injected into subcutaneous tumor xenografts of the EGP-2-positive cell line LS174T. After 2 days, the tumor tissue was evaluated for luciferase expression. As the 3.4 kb EGP-2 promoter showed about 10% of CMV activity (Figure 3d) , this promoter shows a favorable tumor-on/ liver-off profile. Thus, the 3.4 kb EGP-2 promoter fragment controls efficient and selective expression in an adenoviral context, both in vitro and in vivo. The 1.2 kb EGP-2 promoter fragment remains efficient and specific in the adenoviral genome Although the long 3.4 kb EGP-2 promoter is an efficient and specific promoter in vitro as well as in vivo, this fragment will be of limited value when expression cassettes exceed the 7.5 kb insertion size of the adenoviral genome. 17 We therefore truncated the 3.4 kb EGP-2 promoter to 1.2 kb. To test the specificity and activity of this truncated 1.2 kb EGP-2 promoter fragment, the promoter was introduced into the adenoviral genome to drive the expression of luciferase. In EGP-2-positive cell lines, this promoter showed high activity, with levels up to 40% of the CMV promoter. In all EGP-2-positive cell lines tested, the activity of the truncated EGP-2 promoter was slightly increased compared to the 3.4 kb EGP-2 promoter fragment (Figure 4a and b) .
To test whether upstream promoter-like adenoviral sequences interfered with the activity of the truncated 1.2 EGP-2 promoter, 19 we placed the expression cassette in reverse orientation into the adenoviral genome. Overall, there was no clear difference seen between the expression cassette in either orientation (Figure 4a and b) . In the EGP-2-positive cell line SW948 there was no difference in luciferase expression, in the positive cell line LS174T the activity of AdGL3BEGP-2 1.2 kb was increased compared to AdEGP-2 1.2 kb reverse, while in the positive cell line WiDr the luciferase expression of AdEGP-2 1.2 kb reverse was higher.
In the EGP-2-negative cell lines GLC-1 and U373, the luciferase expression of AdGL3BEGP-2 3.4 kb, Ad-GL3BEGP-2 1.2 kb as well as AdEGP-2 1.2 kb reverse was very low (Figure 4a and b) , with values down to 0.06% of CMV activity in U373 for both AdGL3BEGP-2 1.2 kb and AdEGP-2 1.2 kb reverse. Overall, these results demonstrate that the truncated 1.2 kb EGP-2 promoter fragment remains active and specific in an adenoviral context. The 1.2 kb EGP-2 promoter controls selective cell killing by restricted expression of TK The 1.2 kb EGP-2 promoter was subsequently utilized to drive the expression of the suicide gene SR39TK to mediate selective cell killing upon GCV administration. In the EGP-2-positive cell line LS174T, AdEGP-2 SR39TK mediated cell killing as effective as AdCMV SR39TK after GCV administration (Figure 5a ). The IC 50 values were comparable, with 7.571.3 mg/ml GCV (7s.e.m.) for AdEGP-2 SR39TK and 7.371.0 mg/ml GCV (7s.e.m.) for AdCMV SR39TK. On the contrary, in the EGP-2-negative cell line U373, there were no signs of cell death after infection with AdEGP-2 SR39TK and GCV treatment, not even at the highest concentrations of GCV (Figure 5a ). The CMV promoter however did control efficient cell killing, which was comparable with the positive cell line LS174T with IC 50 values of 7.470.77 mg/ml GCV (7s.e.m.).
Also in other positive cell lines, the EGP-2 promoter controlled efficient cell killing at an m.o.i. of 100 PFU/cell as is shown for the cell lines SW948 and WiDr (Figure 5b ). In the positive cell line LS174T, cell death was even more pronounced compared with SW948 and WiDr, showing also cell death at a lower m.o.i. of 10 PFU/cell (Figure 5a and b) . Overall, the 1.2 kb EGP-2 promoter was somewhat less efficient than the CMV promoter, which is in accordance with the luciferase data. Nevertheless, these data clearly demonstrate that the truncated EGP-2 promoter mediates efficient and selective cell killing.
The 1.2 kb EGP-2 promoter shows a liver-off profile in vivo
To test whether the 1.2 kb EGP-2 promoter could prevent TK-induced liver toxicity, either AdEGP-2 SR39TK or AdCMV SR39TK was injected into the bloodstream of mice and GCV treatment was started after 24 h during 3 consecutive days. Macroscopically, liver damage was observed in animals treated with AdCMV SR39TK (Figure 6a ) and high ASAT and ALAT levels were measured in the blood of these mice (Figure 6b ). On the other hand, mice treated with AdEGP-2 SR39TK did not show any signs of liver toxicity. The livers of these animals had the same color as the livers of the control group (Figure 6a) , and also ASAT and ALAT blood values were similar to control animals (Figure 6b ), demonstrating the absence of liver toxicity. Thus, the 1.2 kb EGP-2 promoter remains selective in vivo, preventing TK-induced liver toxicity.
Discussion
In this study, we showed that the EGP-2 promoter could restrict the expression of toxic transgenes to tumor cells in an adenoviral context. When adenoviruses are administrated systemically, most of the virus homes to the liver where the expressed transgene can cause severe liver toxicity. 4, 5 To circumvent this toxicity in the liver, several approaches have been developed to retarget the adenoviral vector. The tropism of the adenovirus can be altered by modifying the adenoviral capsid, and also the expression of transgenes can be restricted to tumor cells. 6 In this study, the latter approach has been explored to target epithelial derived tumors using the tumor-specific promoter EGP-2.
Several other tsp have already been evaluated such as the tyrosinase promoter (Tyr) for melanoma, 11 the secretory leukoprotease inhibitor (SLP1) for ovarian cancer, 27 the PSES promoter for prostate cancer 9 and the cyclooxygenase-2 (COX-2) promoter for gastrointestinal, ovarian and pancreatic cancer. 5, 28, 29 Many tsp are restricted to tumors originating from a specific tissue type. 30 In contrast, the EGP-2 promoter is known to be active in prostate, ovarian, lung, pancreatic and colorectal cancer and many more other carcinomas. 13 Most importantly, the EGP-2 promoter is known to be silent in mature hepatocytes. 16 This indicates that the EGP-2 promoter may be a valuable tool to control transgene expression for many different types of cancer.
It has been demonstrated that adenoviral sequences have promoter-like properties and therefore can induce the transcription of a transgene. 19 For this reason, the 3.4 kb EGP-2 promoter was first evaluated for whether it would maintain its activity and specificity in an adenoviral context. In EGP-2-positive colon carcinoma cell lines as well as in an ovarian cancer cell line, the promoter showed efficient transcriptional activity to levels comparable with other tumor type specific promoters. 27, 28, 31 The 3.4 kb EGP-2 promoter fragment also maintained outstanding selectivity in EGP-2-negative cell lines, with an expression profile comparable with or even more specific than other evaluated tsp. 27, 29, 32, 31 These results demonstrate that the 3.4 kb EGP-2 promoter remained active and specific in an adenoviral context. The specificity of 3.4 kb EGP-2 promoter fragment was subsequently determined in vivo. The transcriptional activity of this promoter in the liver was over 3-log less in comparison with the CMV promoter. This lack of EGP-2 promoter activity is in agreement with previous observations, which demonstrated the absence of EGP-2 in mature hepatocytes. 16 On the other hand, in the intestine, EGP-2 activity was similar to CMV activity. This is expected as the intestine expresses endogenous EGP-2, 33 and therefore reflects an equal biodistribution of both viruses and the potential of the EGP-2 promoter to selectively express transgenes in vivo to a level comparable with the CMV promoter. It has to be kept in mind that the CMV activity was over 4-log less in the intestine compared with the liver, indicating the insignificant risk of toxicity due to transgene expression in the intestine. In addition to the 'liver-off' profile, the 3.4 kb EGP-2 promoter fragment remained active in tumor tissue in vivo. The 3.4 kb EGP-2 promoter fragment demonstrated 8.3% of the activity of the CMV promoter, which is slightly lower compared with, for example, the tsp SLP1 27 and COX-2. 5 Both the COX-2 and the EGP-2 promoter showed an exceptional untargeting of the liver. Overall, this study strongly suggests that the EGP-2 promoter has a very good therapeutic index.
Although the 3.4 kb EGP-2 promoter is a very competent tsp, the large size of this promoter may limit its future applications when more spacious expression cassettes are introduced into the adenoviral genome. Therefore, we evaluated the truncated 1.2 kb EGP-2 promoter. This truncated promoter demonstrated an activity at least as good as the 3.4 kb EGP-2 promoter in EGP-2-positive cell lines. As previously mentioned, it has been demonstrated that adenoviral sequences have the potential to induce transgene expression. 19 To test whether upstream promoter-like adenoviral sequences interfered with EGP-2 promoter-controlled expression, the expression cassette was also placed in reverse orientation into the adenoviral genome. No clear difference in luciferase gene expression was detected when the expression cassette was placed in either forward or reverse orientation. Therefore, increased activities seen with the truncated EGP-2 promoter are not due to upstream adenoviral sequences but can for example be due to the removal of a putative inhibitory transcription factor binding site located between 3.4 and 1.2 kb on the 5 0 end of the EGP-2 promoter. Nevertheless, this observation was not seen in a deletion analysis of the EGP-2 promoter region. 12 The truncated 1.2 kb EGP-2 promoter retained its selectivity in the adenoviral genome. In EGP-2-negative cell lines, the activity of the truncated EGP-2 promoter in both forward and reverse orientation in the adenoviral genome was up to 3-log less when compared with CMV activity, which is similar or even superior to other evaluated tsp. 27, 29, 32, 31 It is still largely unclear why some tsp do not lose their tumor specificity in an adenoviral context, while others do. A deletion analysis of the EGP-2 promoter showed that epithelial specificity is maintained within 687 bp of the 5 0 flanking region. The EGP-2 promoter used in this study is 1.2 kb. This extra length may function as an insulator capable of blocking the transcriptional interference of upstream adenoviral sequences. 34, 35 To demonstrate the utility of the 1.2 kb EGP-2 promoter, we utilized the truncated promoter to drive the expression of the suicide gene SR39TK. SR39TK can convert the nontoxic prodrug GCV resulting in toxic metabolites, ultimately causing cell death and displays a superior sensitivity to GCV compared to wild-type TK. 20, 21 The 1.2 kb EGP-2 promoter controlled selective cell killing of EGP-2-positive cells in a GCV dosedependent manner. However, no toxicity was seen in an EGP-2-negative cell line in contrast to the CMV promoter, which controlled efficient cell killing in all cell lines tested. The eradication of tumor cells was more efficiently mediated by the CMV promoter compared to the EGP-2 promoter, which is consistent with the higher CMV promoter activity seen in these cell lines. More efficient tumor cell killing in vitro controlled by the CMV promoter compared to the tsp has also been observed in other studies. 8, 11, 29 Although the truncated promoter was less efficient compared to the CMV promoter, the EGP-2 promoter could still effectively cause cell death in all evaluated EGP-2-positive cell lines.
The complexity of treating cancer is often caused by the spread of oncogenic cells throughout the body causing the formation of metastases. Therefore, to reach all tumor nodules, systemic administration is necessary. To systemically administrate adenoviral vectors, the utilized tsp must have a very strong 'liver-off' profile. This stringent inhibition of TK expression is also important even without administration of GCV, because TK by itself can also cause liver toxicity. 5 CMV promoter-driven expression of SR39TK did cause major liver toxicity after GCV administration as was shown macroscopically and by the exceptional increase in ASAT and ALAT blood values. In contrast, the truncated EGP-2 promoter-driven TK expression did not cause liver toxicity. We therefore demonstrated in this study that the 1.2 kb EGP-2 promoter does exhibit this 'liver-off' profile.
In conclusion, this study has shown novel powerful applications for the tsp EGP-2. This promoter efficiently and selectively controls the expression of the reporter gene luciferase or the therapeutic gene SR39TK. The EGP-2 promoter is active in most epithelial derived cancers, making it a very promising promoter to target a broad range of tumor types.
